FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis |
News and Updates
eMediNexus Coverage from: 
FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis

1 Read Comments                

The U.S. Food and Drug Administration has expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatment-naïve). Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis… (FDA, September 26, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now